Loading...
Loading...
In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on
Medtronic, Inc.MDT, but removed the $73.00 price target.
In the report, Morgan Stanley noted, “Proposed Treasury rules on inversion could impose additional financing costs on Medtronic but do not appear to derail the transaction entirely. Should Treasury block hopscotch loans as proposed, Medtronic may not be able to use its ~$15 billion in OUS cash to finance the deal. If Medtronic were to raise debt instead, we estimate EPS accretion would decline by about $0.14-0.18 (3-4%) and pro forma total debt / EBITDA would rise to about 3.5x (from 2.0x in our base case). This structure still accesses future cash, is neutral to ROIC and remains value-creating for shareholders.”
Medtronic, Inc. closed on Monday at $65.98.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in